Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Krystal Biotech (KRYS) Equity Ratio (2021 - 2025)

Historic Equity Ratio for Krystal Biotech (KRYS) over the last 5 years, with Q3 2025 value amounting to 0.92.

  • Krystal Biotech's Equity Ratio rose 175.0% to 0.92 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.92, marking a year-over-year increase of 175.0%. This contributed to the annual value of 0.9 for FY2024, which is 579.53% down from last year.
  • Krystal Biotech's Equity Ratio amounted to 0.92 in Q3 2025, which was up 175.0% from 0.91 recorded in Q2 2025.
  • Krystal Biotech's Equity Ratio's 5-year high stood at 0.97 during Q1 2021, with a 5-year trough of 0.89 in Q1 2022.
  • Its 5-year average for Equity Ratio is 0.93, with a median of 0.93 in 2022.
  • Over the last 5 years, Krystal Biotech's Equity Ratio had its largest YoY gain of 367.21% in 2022, and its largest YoY loss of 852.18% in 2022.
  • Krystal Biotech's Equity Ratio (Quarter) stood at 0.95 in 2021, then fell by 1.33% to 0.94 in 2022, then grew by 1.75% to 0.95 in 2023, then dropped by 5.8% to 0.9 in 2024, then rose by 2.37% to 0.92 in 2025.
  • Its last three reported values are 0.92 in Q3 2025, 0.91 for Q2 2025, and 0.92 during Q1 2025.